Why Current PTH Assays Mislead Clinical Decision Making in Patients with Secondary Hyperparathyroidism.
Preclinical studies in cell culture systems as well as in whole animal chronic kidney disease (CKD) models showed that parathyroid hormone (PTH), oxidized at the 2 methionine residues (positions 8 and 18), caused a loss of function. This was so far not considered in the development of PTH assays used in current clinical practice. Patients with advanced CKD are subject to oxidative stress, and plasma proteins (including PTH) are targets for oxidants. In patients with CKD, a considerable but variable fraction (about 70 to 90%) of measured PTH appears to be oxidized. Oxidized PTH (oxPTH) does not interact with the PTH receptor resulting in loss of biological activity. Currently used intact PTH (iPTH) assays detect both oxidized and non-oxPTH (n-oxPTH). Clinical studies demonstrated that bioactive, n-oxPTH, but not iPTH nor oxPTH, is associated with mortality in CKD patients.
Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.
Berthold
B
Hocher
Lianghong
L
Yin
D000066491:Clinical Decision-Making; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood* / Q000737:chemistry; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000150:complications / Q000401:mortality
D010281:Parathyroid Hormone
Dialysis patients ; Mortality; Serum intact-parathyroid hormone level